Melissa Sanford, MD
Urogynecology and Reconstructive Pelvic Surgery · Alhambra, CANPI 1518283795
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.2%), travel and lodging and gifts — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Medtronic at 47.6% of the total. 2025 is the largest year on record at $2,789, 4.5 times the $618 reported in 2019.
Across 105 payments — averaging $82.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Intuitive Surgical$2K
- Coloplast$1K
- Boston Scientific$325
- Coopersurgical, Inc.$318
- Axonics, Inc.$148
- plus $326 from 7 others
What the payments were for
- Travel & lodging$4,27650%
- Food & beverage$4,33650%
- Gifts$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 55 | $4,108 |
| Intuitive Surgical | 12 | $2,033 |
| Coloplast | 16 | $1,376 |
| Boston Scientific | 6 | $325 |
| Coopersurgical, Inc. | 7 | $318 |
| Axonics, Inc. | 1 | $148 |
| AbbVie | 1 | $136 |
| Procept Biorobotics Corporation | 2 | $83 |
| Pacira Pharmaceuticals Incorporated | 1 | $25 |
| Urogen Pharma, Inc. | 1 | $24 |
| Ambu Inc. | 1 | $22 |
| Laborie Medical Technologies Corp. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$2,081
- Da Vinci Surgical System$1,658
- ALTIS$1,021
- ALTAVIVA$830
- Bulkamid$148
- BOTOX COSMETIC$136
- TITAN$130
- Solyx SIS System$129
- AMS 700$125
How this compares
$8,635 in reported general payments places this provider in the 70th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
See all urogynecology and reconstructive pelvic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 182 | $123,507 |
| GemtesaVibegron | 73 | $51,750 |
| Mirabegron ErMirabegron | 24 | $11,979 |
| Estradiol | 158 | $10,879 |
| LinzessLinaclotide | 14 | $10,264 |
| EstringEstradiol | 16 | $8,550 |
| Potassium Citrate ErPotassium Citrate | 24 | $4,179 |
| Trospium Chloride | 51 | $4,078 |
| Trospium Chloride ErTrospium Chloride | 18 | $2,971 |
| Solifenacin Succinate | 70 | $2,951 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 30 | $2,404 |
| Tolterodine Tartrate ErTolterodine Tartrate | 21 | $2,256 |
| Methenamine Hippurate | 42 | $1,709 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 62 | $1,432 |
| Tamsulosin Hcl | 61 | $777 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $18 | $123,507182 claims |
| AbbVieLinzess | $136 | $10,26414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 130 urogynecology and reconstructive pelvic surgery providers in California.
Other urogynecology and reconstructive pelvic surgery in Alhambra
- Andrew BrillSan Francisco$345K
- Bilal KaakiRiverside$301K
- Savitha KrishnanMountain View$243K
- Peter CastilloLos Gatos$95K
- Bruce Kahnla Jolla$79K
- Jennifer GruenenfelderOrange$76K
- Traci ItoSan Francisco$68K
- Tanaz FerzandiLos Angeles$60K
- Sadikah BehbehaniCosta Mesa$53K
- Christopher TarnayLos Angeles$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.